State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Int Immunopharmacol. 2021 Feb;91:107325. doi: 10.1016/j.intimp.2020.107325. Epub 2020 Dec 24.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 2019 (COVID-19), has rapidly spread, resulting in considerable casualties and serious economic loss worldwide. Disease severity and related symptoms markedly vary among individuals. A large number of patients present atypical symptoms, which represent a big challenge for early diagnosis and prompt infection source isolation. Currently, COVID-19 diagnosis predominantly depends on nucleic acid tests (NAT) for SARS-CoV-2 in respiratory specimens, but this method presents a high rate of false negative results. Therefore, serum antibody measurement has been rapidly developed as a supplementary method with the aim of improving diagnostic accuracy. Further, serum antibody levels might help to identify the infection stage, asymptomatic carriers, and patients with diverging severities and to monitor convalescent plasma therapy. In the current review, we aim to present comprehensive evidence to clarify the utility of SARS-CoV-2 antibodies in COVID-19 patients as a reference for use in the clinic.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）可引发 2019 冠状病毒病（COVID-19），其已在全球迅速传播，导致了大量人员伤亡和严重的经济损失。疾病的严重程度和相关症状在个体之间差异显著。大量患者表现出非典型症状，这对早期诊断和及时隔离传染源构成了巨大挑战。目前，COVID-19 的诊断主要依赖于呼吸道样本中 SARS-CoV-2 的核酸检测（NAT），但该方法存在较高的假阴性率。因此，血清抗体检测已迅速发展成为一种补充方法，旨在提高诊断准确性。此外，血清抗体水平可能有助于确定感染阶段、无症状携带者以及病情严重程度不同的患者，并监测恢复期血浆治疗。在本次综述中，我们旨在提供全面的证据，阐明 SARS-CoV-2 抗体在 COVID-19 患者中的应用价值，为临床应用提供参考。
